Alembic Pharma gets USFDA nod for generic high blood pressure treatment drug
Alembic Pharmaceuticals
on Friday said it has received final approval from the US health regulator for its generic version of
amlodipine and atorvastatin
tablets, used to treat high blood pressure. The final approval by the US Food & Drug Administration (USFDA) is for the
abbreviated new drug application
(ANDA) of Amlodipine and Atorvastatin tablets of strengths 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, the company said in a statement.
These are therapeutically equivalent to the reference-listed drug product,
Caduet tablets
of corresponding strengths of Pharmacia and Upjohn Co LLC, it added.
Alembic said it has a cumulative total of 223
ANDA approvals
(199 final approvals and 24 tentative approvals) from the USFDA.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Value Chain
17 hours ago
- Fashion Value Chain
Emcutix Unveils Flawlizo Range for Rapid Acne Relief
Emcutix Biopharmaceuticals Ltd., a subsidiary of Emcure Pharmaceuticals, has entered the anti-acne skincare market with the launch of its Flawlizo Xpert Acne Care range—offering targeted, science-led solutions for fast and effective acne management. The highlight of the consumer range includes: Flawlizo Acne Spot Corrector – a biphasic formulation clinically proven to reduce early breakouts within 3–5 days Flawlizo Acne Care Moisturizing Gel – a non-comedogenic, hydrating solution enriched with natural extracts, designed to nourish acne-prone skin without clogging pores The products are developed to deliver visible results, while maintaining skin barrier integrity and hydration—offering a complete acne care routine that addresses breakout treatment and long-term skin health. In addition to the consumer offerings, the Flawlizo portfolio also includes five prescription-only products featuring Tretinoin, a globally recognized gold-standard acne treatment. These are manufactured at Encube Ethicals, a USFDA-certified facility with one of the largest global capabilities in topical dermatological formulations. Sathya Narayanan, CEO, Emcutix Biopharmaceuticals Ltd., stated: 'Flawlizo reflects our commitment to uniting clinical science with real-world skincare needs. It empowers individuals to manage acne with confidence and care, using safe, effective, and accessible solutions.' This launch reinforces Emcutix's growing footprint in dermatology, spanning prescription, aesthetic, and over-the-counter skincare solutions. The move follows the company's exclusive licensing partnership with WiQo, introducing PRX-PLUS, a non-invasive skin treatment, to the Indian market for the first time.
Hans India
2 days ago
- Hans India
Wockhardt eyes $7 bn mkt opp for antibiotic Zaynich
New Delhi: Drugmaker Wockhardt said its novel antibiotic Zaynich has an addressable market opportunity of $7 billion in the US and Europe. The company said it has completed a pre-NDA (non-disclosure agreement) meeting with the US Food and Drug Administration (USFDA) in May 2025. Filing to the USFDA is slated in the second quarter of the current fiscal with potential launch in FY2026-27, Wockhardt Ltd said in a regulatory filing. The company plans for regulatory approval for the product in Europe and emerging markets in the second half of the current financial year, it added. Wockhardt said it has also filed for approval of Zaynich with the Drug Controller General of India (DCGI) and expects to launch the product in the domestic market in the second half of the current fiscal. The antibiotic, to be used against gram-negative infections, is expected to help 11 lakh cases in India alone, the Mumbai-based drug maker said.
&w=3840&q=100)
Business Standard
2 days ago
- Business Standard
Wockhardt eyes $9 bn market opportunity for novel antibiotic Zaynich
Mumbai-based pharmaceutical major Wockhardt, which is set to launch a new class of antibiotic, Zaynich, in India this year, estimates a total addressable market opportunity of $9 billion. This includes a $7-billion market in the US and Europe, and a ₹17,000-crore opportunity in India. The company's stock rose 2.4 per cent on the BSE on Thursday following an investor presentation outlining its growth plans for the next three to five years. Zaynich (or WCK 5222) is a key research candidate in Wockhardt's pipeline. It has completed global Phase 3 clinical trials, demonstrating a 20 per cent higher (statistically superior) composite cure rate compared to Meropenem, the current gold standard in antibiotics. Wockhardt claims Zaynich is the first new class of antibiotic in over 30 years to treat gram-negative infections. The drug has already saved 51 lives under compassionate use, including three in the US, where patients had failed all existing therapies. Zaynich is indicated for complicated urinary tract infections (UTIs), hospital-acquired and ventilator-associated bacterial pneumonia, bloodstream infections, and complicated intra-abdominal infections. The company expects approval from the Drugs Controller General of India (DCGI) shortly and plans to launch the drug in the second half of this financial year. Wockhardt has completed a pre-NDA (New Drug Application) meeting with the US Food and Drug Administration (USFDA) in May and plans to file in Q2FY26, targeting a potential launch in FY27. Regulatory filings in the EU and emerging markets are scheduled for the second half of FY26. Wockhardt estimates that around 1.1 million patients in India may benefit from Zaynich, while 371,000 carbapenem-resistant cases in the US and Europe are potential candidates. Overall, there are 4.3 million hospitalised cases involving key gram-negative pathogens in the US and EU. The firm sees a combined addressable patient pool of 2 million across India, the US, Europe, and China. Apart from Zaynich, Wockhardt is also betting on other antibiotics in its portfolio, such as Miqnaf (Nafithromycin), and its biotechnology portfolio, including insulin products. Miqnaf, already launched in India, treats community-acquired bacterial pneumonia (CABP) and upper respiratory tract infections. It has received Qualified Infectious Disease Product (QIDP) status from the USFDA, signifying unmet medical need, and Breakthrough Medicinal Product (BMP) designation in Saudi Arabia. Miqnaf targets a ₹10,800-crore market in India, with over 96 million potential prescriptions. In the biosimilars segment, Wockhardt is focusing on diabetes care and sees significant opportunity arising as Danish major Novo Nordisk phases out human insulin cartridges. This creates a ₹450-crore opportunity in India and a $157-million market across emerging economies. With only three major players in India, including itself, Wockhardt expects to benefit substantially. The company is doubling its diabetes biosimilars capacity over the next three years to meet growing demand, targeting business growth of 20–25 per cent.
